The treatment of acute myeloblastic leukemia (AML) has been considerably modified over the years. The Argentine Group for the Treatment of Acute Leukemia (GATLA) was created in 1967 with the purpose of investigating and promoting the development of treatment strategies in acute leukemia. GATLA developed seven consecutive trials for pediatric AML treatment between 1967 and 1997. The complete remission (CR) rate of the 272 children allocated to the first five protocols performed between 1967 and 1983 was 50%. Event-free survival (EFS) at 60 months was only 3%; the median duration of continuous CR was 9 months. In an attempt to improve these results, GATLA adopted the BFM strategies in 1983. From then to 1997, 368 eligible patients with acute myeloid leukemia (AML) were treated according to two consecutive trials: AML-GATLA 83 and AML-GATLA 90.
Patients with myelosarcoma without bone marrow involvement, Down's syndrome, secondary AML, myelodysplastic syndrome or over 14 years of age at diagnosis were analyzed separately. Thus, in the present report, 334 patients under 15 were evaluated, 155 patients in the first trial (from March 1983 to March 1990) and 179 patients in the AML-GATLA 90 (from April 1990 to March 1997). No major clinical differences in patients' initial data between AML-GATLA 83 and AML-GATLA 90 were observed. AML-GATLA 83 based on AML-BFM 78 consisted of a long induction-consolidation phase, with six drugs: vincristine (V), adriamycin, cytarabine (ARA-C), prednisolone, 6-mercaptopurine (6-MP) and cyclophosphamide (Cyclo) for 8 weeks, followed by nonmyeloablative maintenance for 2 years. Owing to the unavailability of certain drugs and in order to standardize the treatments throughout the institutions involved in the trial, GATLA had to introduce a number of changes, as follows: 6-MP was used instead of 6-thioguanine; subcutaneous ARA-C was used instead of intravenous infusion; Cyclo doses were increased from 500 to 1000 mg/m 2 and administered weekly (four doses); and adriamycin was not administered during consolidation phase. Central nervous system (CNS) prophylaxis was performed with intrathecal chemotherapy alone: methotrexate (MTX) and dexamethasone (DXM) were administered during consolidation; after that, bimonthly, during the first year of maintenance, and every 3 months during the second year. Cranial radiotherapy was reserved for patients with CNS disease at diagnosis.
The encouraging results obtained with the AML-GATLA 83 protocol 1 led GATLA to start the BFM 87-based AML-GATLA 90 study in 1990. However, in this study, idarubicin was substituted for daunorubicin (AIE) in the 8-day induction phase with ARA-C, daunorubicin and etoposide (ADE). 2 The rationale for this substitution was based on previous studies proving its usefulness, either alone or in combination with ARA-C in patients with AML in relapse. It had already been used as firstline treatment, showing lower cardiotoxicity.
Once CR was achieved, consolidation consisted in the 6-week administration of six drugs, similar to those used in the induction-consolidation phase of the previous trial. Since adriamycin was added, Cyclo was decreased from 1000 to 500 mg/m 2 /dose; and from four to two doses in order to reduce toxicity. This combination of drugs with no crossresistance improved previous GATLA results. Once consolidation was finished, children with a matched sibling donor were eligible for allogeneic stem cell transplantation (SCT) in first remission. In case a donor was not available, an intensification phase was initiated with two cycles of high-dose ARA-C and etoposide. After that, maintenance was performed with daily 6-MP and monthly subcutaneous ARA-C. The treatment was completed after 18 months.
The prevention of CNS relapses, as known from our previous GATLA experience (Protocols 73-83), was performed with intrathecal chemotherapy alone (ARA-C and DXM). Following the AML-BFM 87 protocol, ARA-C was substituted for MTX.
In case of CNS disease, intrathecal chemotherapy was administered weekly, over a 6-week period; cranial irradiation was performed (24 Gy) after consolidation in the AML-GATLA 83 study and after intensification, in the AML-GATLA 90 study.
Since all-trans retinoic acid (ATRA) for the treatment of acute promyelocytic leukemia (APL) in pediatric patients became widely used in Argentina as from 1996, it was not included in these studies.
Overall results of both studies are shown in Table 1 . In AML-GATLA 83, 108 (69.7%) out of 155 patients achieved CR. Estimated probabilities of survival, EFS and disease-free survival (DFS) at 5 years were 3074, 2674 and 3875%, and at 10 years were 2974, 2474 and 3575%, respectively. In AML-GATLA 90, 125 (69.8%) out of 179 patients achieved CR. Estimated probabilities of survival, EFS and DFS at 5 years were 4174, 3174 and 4375%, and at 10 years were 3774, 2774 and 3875%, respectively. The probabilities of survival, EFS and DFS did not significantly improve in these two consecutive studies. Early-death rate (before therapy or during the first 42 days) showed almost no difference: 17.4% in AML-GATLA 83 and 19.6% in AML-GATLA 90. The cumulative incidence of toxic death in CR was similar in both studies: 6.573% in the first and 6.873% in the second. The early-death rate before day 15 was 5.8% in AML-GATLA 83 and 8.4% in AML-GATLA 90; fatal events were mainly due to CNS hemorrhage. Death rate between day 15 and 150 was 23.9% in the first trial, and 19.0% in the second one; fatal events were mainly due to sepsis. The percentage of nonresponders was similar: 12.9% in study 83 and 10.6% in study 90. The primary reason for treatment failure was marrow relapse; in AML-GATLA 83, the cumulative incidence of relapses was 37.278% (CNS 2%), and in the second trial, 30.977% (CNS 1.2%). Although the percentage of bone marrow relapses was similar to that shown in other international studies, [3] [4] [5] we did not significantly improve the results despite the introduction of intensive induction with AIE. 2, 6 The high death rate during induction and CR makes it difficult to evaluate the efficacy of the chemotherapy schedule itself in our group of patients. Compared with other international trials in AML, 5,7 the AML-GATLA protocols had higher early and toxic death rates, possibly due to the discouraging economic and social situation.
No patients received allogeneic SCT in AML-GATLA 83. In AML-GATLA 90, only five patients received an allogeneic matched sibling donor SCT in first CR, out of whom, three are alive. The limited number of patients did not allow us to draw any conclusions. Table 2 shows the impact of several potential prognostic factors. Patients with white-blood cell (WBC) count higher than 100 Â 10 9 /l proved to have very bad prognosis in both studies. In AML-GATLA 83, EFS for patients with WBC under 100 Â 10 9 /l was 30 vs 5% for patients with more than 100 Â 10 9 /l (P ¼ 0.026), and in AML-GATLA 90, it was 33 vs 6% (P ¼ 0.016). Cytogenetic studies began with AML-GATLA 90. These studies showed a significantly better outcome for those patients with favorable findings: t(8;21), t(15;17) and inv(16). In patients with favorable karyotypes, a 5-year EFS of 65% was observed, whereas those with unfavorable cytogenetics showed a 5-year EFS of 27% (P ¼ 0.006). In trial AML-GATLA 83, no difference was found regarding EFS and overall survival between children under or over 2 years of age. In trial AML-GATLA 90, children under 2 years of age had worse EFS -16% against 36% (P ¼ 0.004). A higher early-death rate (28%) was observed during or after AIE induction in the group of younger children. This percentage might be explained because chemotherapy doses were not reduced for this group. In our trials, the incidence of FAB M5 was not higher in this age group, as suggested in current literature. 8 The results in both studies have shown a clearly better prognosis for patients with less than 5% blast count on day 15 BM aspiration; in AML-GATLA 83, EFS of 48 vs 22% (P ¼ 0.003), and in AML-GATLA 90, EFS of 40 vs 27% (P ¼ 0.044).
Unlike other reports, EFS according to FAB types was not statistically different in our studies, their distribution was similar to those reported in the literature. However, the percentage of FAB M3 was higher: 19.2% in AML-GATLA 90 and 5.8% in AML-GATLA 83. The difference between these two studies may be explained in terms of the more accurate diagnosis made in GATLA 90. In AML-GATLA 90, 33 children with APL were evaluated; out of them, 23 achieved CR (69.7%). EFS at 5 years was 38% and early-death rate was higher than in other FAB subtypes -27% against 16.5%, but this difference was not statistically significant (P ¼ 0.155). In AML-GATLA 90, APL patients had the same outcome as children with other FAB subtypes regarding early death, overall survival and EFS, probably because they did not receive ATRA.
Remarkably, with the introduction of AML-GATLA 83, the 5-year EFS significantly improved to 26 vs 3% (P ¼ 0.001) obtained in previous GATLA studies (Figure 1 ). AML-GATLA 90 yielded similar results; overall survival at 5 and 10 years was 11 and 8% higher than in AML-GATLA 83, respectively, but these differences were not statistically significant (Figure 2) . Relapse remains the main reason for failure in AML therapy; however, prevention of any other event is also important in AML due to the high number of deaths in aplasia and in CR. These results (5) 38 (5) a Cummulative incidence. Correspondence show a slightly better rate in the last study despite the use of more intensive induction (AIE). The GATLA experience using intrathecal chemotherapy as CNS prophylaxis has had excellent results with p2% CNS relapse rate.
In conclusion, the introduction of BFM strategies in our group allowed a significant improvement in the treatment of pediatric AML in Argentina, which has led to an overall survival increase from less than 5% in the 1970s and early 1980s to 35-40% as from the 1990s. AML-GATLA 83 and AML-GATLA 90 survival. Kaplan-Meier curves for the overall survival of 334 patients treated according GATLA-AML 83 and GATLA-AML 90 protocols.
